Hydrochlorothiazide: Nursing Drug Guide, Hypokalemia & NCLEX Review

Microzide is a widely recognized U.S. brand for hydrochlorothiazide capsules and tablets. Generic hydrochlorothiazide is available as oral tablets in 12.5 mg, 25 mg, and 50 mg strengths. Verify tablet strength on every pass—12.5 mg, 25 mg, and 50 mg are not interchangeable without a prescriber order.

Many antihypertensive regimens combine hydrochlorothiazide with ACE inhibitors (for example lisinopril–HCTZ fixed-dose products) or other diuretics; confirm whether combination therapy is intentional before questioning duplicate thiazide orders. Clinicians may choose chlorthalidone instead when they want a longer-acting thiazide-like agent—never convert between thiazides without pharmacist verification.

U.S. prescribing information lists hydrochlorothiazide as adjunctive therapy for edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also used for edema due to various forms of renal dysfunction and in the management of hypertension—either alone or to enhance other antihypertensive drugs in more severe hypertension.

↔On a small screen, swipe or scroll sideways to see the full table.

Hydrochlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption, increasing excretion of sodium and chloride in approximately equivalent amounts. Natriuresis is accompanied by loss of potassium and bicarbonate—nurses should anticipate hypokalemia, hyponatremia, hypochloremic alkalosis, and hypomagnesemia. Unlike loop diuretics such as furosemide, thiazides have a lower diuretic ceiling but remain a first-line oral option for hypertension and mild-to-moderate edema when potassium and renal function are monitored.

Individualize to the smallest dosage necessary for the required response. Labeling emphasizes careful medical supervision because electrolyte depletion and dehydration can develop with excessive diuresis.

Renal impairment: Use with caution in severe renal disease; thiazides may precipitate azotemia and cumulative effects may develop in impaired renal function per labeling.

Hepatic impairment: Use with caution in impaired hepatic function or progressive liver disease—minor fluid and electrolyte shifts may precipitate hepatic coma.

Pediatrics: Usual pediatric dose 1–2 mg/kg/day (max 37.5 mg/day in infants up to 2 years or 100 mg/day in children 2–12 years) per labeling; no well-controlled trials in pediatric patients.

Missed dose: Not specified in the reviewed prescribing information; follow prescriber or pharmacy guidance.

• Oral: Diuresis begins within 2 hours; peaks in about 4 hours; lasts approximately 6 to 12 hours per labeling
• Half-life: Plasma half-life varies between 5.6 and 14.8 hours; at least 61% of oral dose eliminated unchanged within 24 hours
• Metabolism: Not metabolized; eliminated rapidly by the kidney
• Distribution: Crosses placenta; excreted in breast milk; does not cross blood-brain barrier per labeling

Pretreatment checks

• Latest BMP: potassium, sodium, chloride, bicarbonate/CO₂, creatinine, BUN, glucose
• Baseline weight, blood pressure, and orthostatic vitals when diuresis is active
• Confirm patient is not in anuria; review allergies (hypersensitivity to sulfonamide-derived drugs per labeling)
• Review interacting drugs: digoxin, ACE inhibitors, NSAIDs, lithium, corticosteroids

Contraindications

• Anuria
• Hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Oral only: Tablets 12.5 mg, 25 mg, or 50 mg. Many regimens give a single morning dose to limit nocturia; follow the MAR exactly. When combined with cholestyramine or colestipol resins, absorption of hydrochlorothiazide may be reduced—separate administration per pharmacy guidance.

• Verify tablet strength (12.5 vs 25 vs 50 mg) before every administration
• Give with or without food per institutional policy; many patients tolerate morning dosing with food
• Pair each dose with accurate orthostatic blood pressure checks when diuresis is brisk or dose was recently increased
• Perform medication reconciliation at transitions—home HCTZ plus inpatient combination products can duplicate thiazide therapy

• Increased urine output within the expected 2–4 hour onset window after oral dosing
• Decrease in edema, weight, or congestion symptoms when treating fluid overload in heart failure
• Blood pressure reduction when used for hypertension (monitor for excessive drop when combined with other antihypertensives)
• Stable mentation and perfusion without progressive orthostatic symptoms as diuresis continues

Electrolyte loss and volume depletion can progress over days of thiazide therapy—especially with doses above 50 mg, combination diuretic therapy, or inadequate oral potassium intake.

• Potassium below prescriber or protocol hold limit, new PVCs or ventricular ectopy, or digoxin on the MAR with falling K⁺
• Acute weight loss, orthostatic hypotension, oliguria, or confusion suggesting hypovolemia or worsening renal perfusion in chronic kidney disease
• Marked rise in BUN/creatinine during diuresis—labeling indicates withholding or discontinuing diuretic therapy if progressive renal impairment becomes evident
• Muscle cramps, weakness, tetany, or palpitations with electrolyte depletion on BMP
• Acute onset decreased visual acuity or ocular pain—labeling warns of acute transient myopia and angle-closure glaucoma with sulfonamide-derived drugs
• Severe hypersensitivity, systemic vasculitis, or interstitial nephritis (reported per labeling)

↔On a small screen, swipe or scroll sideways to see the full table.

Whenever adverse reactions are moderate or severe, hydrochlorothiazide dosage should be reduced or therapy withdrawn per labeling.

The most common signs and symptoms of overdose are electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis per labeling. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.

Antidote

Not specified in the reviewed prescribing information — there is no listed specific reversing agent. Treatment is supportive.

Management per labeling

• Employ symptomatic and supportive measures; induce emesis or perform gastric lavage when clinically appropriate
• Correct dehydration, electrolyte imbalance, hepatic coma, and hypotension by established procedures
• Coordinate potassium replacement per prescriber orders—often potassium chloride when safe
• The degree to which hydrochlorothiazide is removed by hemodialysis has not been established
• Contact local poison control or medical toxicology services per facility protocol for significant overdose or instability

• Hydrochlorothiazide vs chlorthalidone vs chlorothiazide — all thiazide-class diuretics with different potency and duration; never convert doses without pharmacist verification
• HCTZ abbreviation — verbal orders may be misheard; confirm full drug name and strength in writing
• 12.5 mg vs 25 mg vs 50 mg tablets — triple-check strength; doses above 50 mg increase potassium loss per labeling
• Combination products — lisinopril-HCTZ and other fixed-dose tablets embed a thiazide; scan for duplicate diuretic ingredients
• Duplicate thiazide therapy — home HCTZ plus inpatient combination ordering errors; perform medication reconciliation at every transition

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Serum electrolytes (especially potassium and sodium), CO₂, creatinine, and BUN—periodically at appropriate intervals per labeling
• Weight, I&O, blood pressure, and orthostatic vitals during active diuresis
• Telemetry or rhythm assessment when digoxin is co-prescribed and potassium is trending down
• Glucose in diabetic patients; magnesium periodically per labeling
• Signs of dehydration, orthostatic symptoms, and acute vision changes

Document

• Dose, time, tablet strength, indication, urine output response, and weight change
• Latest BMP values and any hold parameters triggered
• Orthostatic vital sign findings when symptomatic
• Patient teaching on cramps, dizziness, daily weights, and when to report symptoms

• Report muscle cramps, weakness, dizziness on standing, palpitations, or decreased urination promptly
• Weigh yourself daily at the same time with similar clothing if instructed for heart failure management
• Do not take OTC NSAIDs without asking your prescriber—they can reduce diuretic and antihypertensive effect
• Take potassium supplements or eat high-potassium foods only as directed; do not self-treat low potassium
• Protect skin from sun; hydrochlorothiazide may increase photosensitivity—undergo regular skin cancer screening per labeling patient information
• Rise slowly from sitting or lying down to reduce orthostatic dizziness

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for hydrochlorothiazide using a tabbed hypertension/heart-failure case (MAR, labs, I&O, nursing notes), then priority action, cue recognition SATA, electrolyte trend SATA, matrix urgency sorting, oral dose judgment, and overdose cloze—with explicit evaluate outcomes items after potassium replacement.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.